Floatz logo

cc-5013

Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary

National Cancer Institute (NCI)Phase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

29 Active assets in the Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary cohort.

Asset / SponsorPhaseRating
Carboplatin
Neonc Technologies, Inc.
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
University of Oxford
Phase 3BB
Docetaxel
Hummingbird Bioscience
Phase 2BB
Eloxatin
University of Oxford
Phase 3BB
Fibrin Sealant
Oxford University Hospitals NHS Trust
Phase 4BB

View all 50 →

Same molecule, other indications

cc-5013 is also rated in:

B-cell non-Hodgkin lymphomaDormant
BBB
Indicative ·
75 / 100
View asset →
Recurrent Adult Hodgkin LymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
adult T-cell leukemia/lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →